Kornimate/medical-research-clean huggingface dataset:
accuracy of tooth modified scan bodies as a novel technique

Conditions: Digital Technology; Dental

Summary: the clinical performance of a novel scan body tooth modified scan body (tmsb) in the degree of trueness of ios impression for full arch cases. i

the clinical performance of a novel scan body tooth modified scan body (tmsb) in the degree of trueness of ios impression for full arch cases. tmsb is a scan body to which different teeth are attached directly as one piece, this may enhance the accuracy level by filling the gabs between isb as well as acting as a stable artificial ai-easily recognized landmarks thus facilitating the scanning procedure. os impression utilizing tooth modified scan bodies or conventional scan bodies result in the same degree of trueness as conventional verified splinted open tray impression. to our knowledge, it is the first time in the literature to utilize a novel scan body modified with directly connected teeth as artificial landmarks in vivo.

Eligibility criteria:
inclusion criteria: * participants who had received 4-6 implants in 1 edentulous arch. * participants with 1-piece implant-supported complete-arch fixed dental prostheses. * systemically free. * primary implant stability exceed 72 the day of the definitive impression. exclusion criteria: * smoker's. * non co-operative patients.

Keywords: jaw relation scan body
vivity study in taiwan

Conditions: Cataract

Summary: the aim of study is to evaluate the quality of vision after bilateral vivity or vivity toric edof iols implantation in taiwan.

this study was a prospective, single arm study. the inclusion criteria for this study were the presence of cataracts in both eyes and corrected distance visual acuity (cdva) of both eyes under 20/40, who received bilateral vivity iol implantation after cataract surgery, targeting emmetropia or mini-monovision of both eyes. phacoemulsification cataract surgery was performed on all patients. the exclusion criteria were complicated cataract; corneal opacities or irregularities; severe dry eye (schirmer's test i ≤ 5 mm); amblyopia; anisometropia; surgical complications such as posterior capsular bag rupture, vitreous loss, or iol tilt/decentration; coexisting ocular pathologies such as glaucoma, nondilating pupil, history of intraocular surgery, refractive surgery, or retinopathy; optic nerve or macular diseases; and refusal or inability to maintain follow-up. when corneal astigmatism was more than 0.75 diopters (d), a toric iol was implanted.

Eligibility criteria:
inclusion criteria: * patients with age-related cataract requiring surgery treatment * patient who received bilateral, uneventful implantation of vivity iols * patient's iol power is between 10-30d, and t2-t6 for toric correction * cataract grade 0\~3 based on the wisconsin cataract grading system • exclusion criteria: * cataract grade 4\~5 based on the wisconsin cataract grading system * patient's iol power is outside of 10-30d or t2-t6 for toric correction * patient with the following ocular comorbidities: * corneal opacities or irregularities; * severe dry eye; * amblyopia; * glaucoma; * non-dilating pupil; * history of intraocular surgery, laser therapy, or retinopathy; * optic nerve or macular diseases; * uncontrolled diabetic mellitus or systemic immune disease; * refusal or unable to maintain follow-up

Keywords: intraocular lens extended depth of focus
enhanced recovery protocol in urogynecologic surgery

Conditions: Urinary Incontinence; Cystocele; Rectocele; Pelvic Organ Prolapse

Summary: enhanced recovery after surgery (eras) has been shown to improve postoperative outcomes in a variety of surgical conditions. however, data regarding its role in urogynecologic surgery is limited. this study aimed to investigate the role of the eras protocol on postoperative outcomes in patients undergoing urogynecologic surgery.

enhanced recovery after surgery (eras) or in other words "fast-track" protocol roughly purposes to improve patient satisfaction, reduce complications and shorten the hospital stay. chronic diseases, nutrition, and any volume depletion are corrected prior to surgery and less invasive surgical techniques are utilized to this end the impact of eras protocols in decreasing length of stay (los), reducing postoperative pain, improving early ambulation and decreasing the rate of potentially serious medical complications have been studied in patients undergoing colorectal, urologic, gastric and pancreatic surgery previously. however, data regarding the role of eras protocol in improving postoperative outcomes and postoperative compliance in patients undergoing urogynecological surgery is limited. the present study purposes to clarify the role of the eras protocol on postoperative outcomes in patients undergoing urogynecologic surgery.

Eligibility criteria:
inclusion criteria: * age must be \> 18 years * must be scheduled for urogynecologic surgery exclusion criteria: * emergency surgery * presence of preoperative sepsis * presence of advanced liver or kidney disease
high protein diet and physical activity in copd

Conditions: COPD

Summary: copd outpatients with severe and very severe (grade iii-iv) disease at risk of malnutrition commencing rehabilitation (7-10-week physical activity program) were randomized to receive a high protein diet (≥ 25 energy percentage) or standard care.

peripheral muscle function was measured by 6mwd (6-meter-walk-distance) and handgrip strength; ffm was measured by bioimpedance, mid upper arm circumference, and mid-thigh circumference; quality of life was measured by cat (????); and dyspnoea was measured by the medical research council dyspnoea scale and borg scores at baseline and after 12 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed copd stage iii or stage iv * nutritional risk by screening (nrs-2002)(kondrup et al, 2002) and/or low-fat free mass (ffmi) (≤ 15% for women and ≤ 16% for men) measured by bioelectrical impedance analysis (bia) exclusion criteria: * terminal phase of copd * lung transplanted patients * severe comorbidities influenzing the end-points (pancreatic insufficiency, severe hepatic failure, inflammatory gastrointestinal disease) * multiple sclerosis * any unwillingness or inability (e.g. not able to make notes of their nutritional intake, come to consultations or manage oral intake)
a study to evaluate sintilimab plus lenvatinib as adjuvant therapy in hepatocellular carcinoma with portal vein tumor thrombosis (pvtt) after surgical resection

Conditions: Hepatocellular Carcinoma

Summary: to compare the impact on recurrence risk of adjuvant sintilimab (a recombinant fully human anti-pd-1 monoclonal antibody) plus lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (pvtt ) after hepatectomy.


Eligibility criteria:
inclusion criteria: * subjects with a histopathological diagnosis of hcc * undergone a curative resection * pathologically confirmed hcc with portal vein tumor thrombus (pvtt) * aged 18-75 years * no previous systematic treatment and locoregional therapy for hcc prior to randomization * no extrahepatic spread * full recovery from curative resection within 4 weeks prior to randomization * child-pugh: grade a or b(7) * ecog-ps score: 0 or 1 * adequate organ function exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, mixed cholangiocarcinom or recurrent hcc * any preoperative treatment for hcc including local and systemic therapy * have received more than 1 cycle of adjuvant tace following surgical resection * any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug * subjects with inadequately controlled hypertension or history of hypertensive crisis or hypertensive encephalopathy * active or history of autoimmune disease * thrombosis or thromboembolic event within 6 months prior to the start of study treatment * any persistent serious surgery-related complications; esophageal and/or gastric variceal bleeding within 6 months * abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * inability or refusal to comply with the treatment and monitoring

Keywords: programmed cell death 1 lysine kinase inhibitor immunotherapy adjuvant hepatocellular carcinoma portal vein tumor thrombus,pvtt
comparison of the efficacy of tidal volume breathing and vital capacity breathing during high-flow nasal oxygen

Conditions: Adult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General Anesthesia

Summary: the purpose of this study is to compare the preoxygenation efficacy of tidal volume breathing and vital capacity breathing.


Eligibility criteria:
inclusion criteria: -adult patients 20 years of age or older who are planning to undergo surgery under general anesthesia exclusion criteria: -basal skull fracture, 2번 - facial anomaly, 3번 - consciousness disorder, 4번 - risk of aspiration
emotional impact of the way conducting cancer patients to the surgical center

Conditions: Anxiety Disorders; Depression

Summary: cancer is an extremely aggressive disease, anxiety and depression are consequences some patients may develop from diagnosis continuing during treatment. a measures control of the cancer is surgery for removal tumor. the surgical procedure is often a difficult experience for patients and their relatives, and patients in the preoperative period are often psychological symptoms of anxiety and depression. a previous study with the objective analyzing patient's emotional repercussion according the type of transport to the surgical center reached the following result: patients who go to the surgical center feel more relaxed in the preoperative period. the primary objective is to analyze emotional repercussion of patient diagnosed with cancer classified in eastern cooperative oncology group (ecog) performance status 0 and 1 according type transport to the surgical center.

a randomized clinical trial, prospective collection to be performed at the barretos cancer hospital, will be include 176 patients, 88 patients being allocated to transport to operating room by stretcher on wheels (group 1) and 88 patients being allocated to transport to operating room by ambulation (group 2). patients with indication elective surgery that meet the inclusion criteria will be included, and randomized for one of the groups, and may be referred by stretcher on wheels to the surgical center (group 1) or referred to the surgical center by ambulation (group 2). the hospital anxiety and depression scale (had) and the survey developed for the present study sati-cir, evaluation questionnaire of satisfaction with healthcare in surgery, will be the instruments used in data collection. participants will respond both after the course to the surgical center.

Eligibility criteria:
inclusion criteria: * diagnosed cancer * age ≥18 years, ≤ 70 years * both sexes * eastern cooperative oncology group (ecog) performance status (ps) score 0 or 1 * patients classified as zero or low risk by the fall risk assessment scale * indication elective surgery exclusion criteria: * patients who present moments before surgery has an adverse event that could jeopardize the ambulation to the surgical center. * patients who are physically disabled and require assistance walking. * patients has indication bed in the intensive care unit (uti) * patients has previously diagnosed psychiatric disorders (severe depression, anxiety disorder, panic, among others). * patients doens't have an accompanying person on the day of surgery. * patients taking anxiolytic and antidepressant medications.

Keywords: anxiety disorders depression transport to operating room
pilot trial of opioid taper support

Conditions: Chronic Non-cancer Pain

Summary: the proposed research will develop, demonstrate the feasibility of, and pilot test in a randomized controlled trial a prescription opioid taper support intervention. this intervention aims to prevent opioid misuse and adverse events among patients receiving chronic opioid therapy for chronic non-cancer pain without evidence of current substance abuse. the project will yield information essential to planning a future, larger-scale rct designed to evaluate: 1) the efficacy of the intervention in preventing prescription opioid abuse, misuse, overdose and other adverse events among patients receiving chronic opioid therapy for chronic non-cancer pain, 2) the effects of the intervention on opioid use, pain, pain related activity interference, and mood. participants in our pilot study will be limited to those without current opioid abuse or other substance abuse, but past substance abuse will be allowed. this will provide a sample of patients at risk for opioid abuse, misuse and overdose, but who may be able to taper their opioids successfully. hypothesis: patients receiving chronic opioid therapy for chronic non-cancer pain who are randomized to the opioid taper support intervention, as compared with patients randomized to usual opioid prescribing care, will have lower opioid average daily doses at 22 and 34 weeks.


Eligibility criteria:
inclusion criteria: * age 18-80 years; * cncp, defined as pain on more than half the days in the past six months, where indicated diagnostic workup is complete and treatment is focused on pain; * currently on cot, defined as self-report of prescribed oral opioid medication use on a daily or near-daily (\>90% of days) basis for 90 days or more; * mean daily opioid dose in the past 30 days of 25 mg med or greater; * willing to participate in the study arm to which they are randomly assigned (including opioid taper in-person sessions if randomized to that group); * able to read, speak, and write english. exclusion criteria: * currently receiving treatment for cancer (other than non-melanoma skin cancer); * medical comorbidity with life expectancy less than a year (based on medical record review by the pi); * recent use (past month) of parenteral, transdermal, or transmucosal opioids, * currently residing in nursing home; * currently using intrathecal pump for pain control; * any current substance abuse according to the dsm-iv checklist (nicotine and marijuana will be allowed since washington state allows medical marijuana for pain control); * presence of illicit drug metabolite in baseline urine drug test, * psychotic symptoms, psychiatric hospitalization or suicide attempts in the past year; * current suicidal ideation with specific plan or intent; * significant cognitive impairment (on 6-item screener scale).

Keywords: chronic non-cancer pain opioid taper chronic pain self-management motivational interviewing
is covid-19 transmitted through human milk? implications for breastfeeding and human milk banking-study 1b

Conditions: Sars-CoV2; Breastmilk

Summary: the canadian paediatric society recommends breastfeeding during covid-19 infection. human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. when mothers of hospitalized infants are unable to supply their milk, the recommended supplement is human donor milk. the impact of a pandemic on human milk banking is unknown. this study seeks to address this public health issue. donor milk will be collected from the rogers hixon ontario human milk bank at sinai health system in toronto. samples will be analyzed for the covid-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding donor milk banking to protect the health of infants.


Eligibility criteria:
inclusion criteria: - human milk donor for the rogers hixon ontario human milk bank exclusion criteria: - none
daily tenofovir df to prevent hiv infection among sex workers in cambodia

Conditions: HIV Infections; HIV Seronegativity

Summary: tenofovir disoproxil fumarate (also known as tenofovir df or viread) is used with other anti-hiv drugs to treat hiv infection. taking tenofovir df every day may also prevent hiv infection. this study will determine if taking a tenofovir df tablet every day is safe and effective in preventing hiv infection. participants in the study will be sex workers in phnom penh, cambodia.

cambodia has one of the highest rates of hiv infection in southeast asia. at the end of 2002, hiv infection rates among cambodian sex workers ranged from 14.8% to 28.8%. tenofovir df is a nucleotide reverse transcriptase inhibitor (nrti) that was licensed for the treatment of hiv-1 infection by the united states food and drug administration (fda) in october 2001. this randomized clinical trial will determine if a daily oral 300 mg dose of tenofovir df is safe and effective in preventing hiv-1 infection. this is a collaborative study between the university of california, san francisco, the university of new south wales, and the ministry of health of cambodia. nine hundred and sixty hiv uninfected female sex workers in phnom penh will be enrolled in the trial. participants will be randomized to receive either 300 mg of tenofovir df or placebo daily for 12 months. participants will be evaluated for rates of hiv infection, adherence to the drug regimen, and changes in risk behaviors. all participants will be monitored throughout the trial for side effects and toxicity. participants will be involved in the study for 14 months.

Eligibility criteria:
inclusion criteria * hiv uninfected * report receiving money or gifts for vaginal or anal sexual intercourse in the year prior to study entry * able to provide a street address of residence for themselves and two personal contacts who would know their whereabouts during the study period * normal lab values within 14 days of study entry * ability to understand spoken khmer * willing and able to provide written informed consent exclusion criteria * pregnant or breast-feeding * previously diagnosed active or serious infections * certain medications * active alcohol or drug abuse that could interfer with the study * previously diagnosed malignancies other than basal cell carcinoma * any other condition that, in the opinion of the study officials, would preclude informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Keywords: hiv prevention
determinants of rescue ventilation requirement in airway surgery under general anesthesia with thrive

Conditions: Subglottic Stenosis (SGS)

Summary: the anesthesia and surgical procedures from the time the patient enters the operating room to discharge from the recovery room are identical to those used in conventional airway surgeries performed under general anesthesia with transnasal humidified rapid-insufflation ventilatory exchange (thrive). the time point at which rescue ventilation is required due to a drop in oxygen saturation below 92% during anesthesia will be recorded, and the predictive factors for this event will be investigated.


Eligibility criteria:
inclusion criteria: * adult patients undergoing elective airway surgery under general anesthesia with transnasal humidified rapid-insufflation ventilatory exchange (thrive) * patients who provide written informed consent exclusion criteria: * patients who decline to participate in the study
use of nitazoxanide and probiotics in acute diarrhea secondary to rotavirus

Conditions: Diarrhea; Rotavirus Infection

Summary: nitazoxanide has proved an cytoprotective effect against rotavirus infection. how it could be clinically important in time of hospitalization and reduction of duration of diarrhea secondary to rotavirus?

nitazoxanide has demonstrated a cytoprotective effect against rotavirus, reducing duration time of diarrhea in comparison to placebo in previous studies. in the current study, based in those results, we design a randomized single-blind controlled trial, in order to asses the effectiveness of nitazoxanide and probiotics in comparison with a control group

Eligibility criteria:
inclusion criteria: * positive stool sample for rotavirus test exclusion criteria: * severe malnourishment * severe dehydration * history of diarrhea more than 3 days previous hospitalization * use of antibiotics, probiotics or nitazoxanide 3 weeks before admission * systemic infections * severe chronic disease * mixed enteric infections besides rotavirus

Keywords: nitazoxanide probiotics diarrhea rotavirus children
how to test success of a renal denervation

Conditions: Hypertension, Resistant to Conventional Therapy

Summary: the study aimed to assess the success of a clinically indicated renal denervation by different tests and correlate the results of the tests with the clinical outcome.

we aim to test the response to adenosine infusion, cold pressure test, flow mediated dilation of renal artery before and after a clinical indicated renal denervation. renal denervation is not a study intervention

Eligibility criteria:
inclusion criteria: male and female patients 18 years to 85 years of age, with a diagnosis of re-sistant hypertension (office sitting blood pressure \>140/90 mmhg and 24-hour blood pressure \>130/80 mmhg in patients treated with at least three antihypertensive drugs including a diuretic) and a clinical indication for a renal denervation. exclusion criteria: * secondary cause of hypertension * anatomical contraindication to renal denervation (renal artery diameter less than 4 mm or more than 8 mm), multiple renal artery, length to bifurcation less than 2 cm * heart failure (normal ejection fractions on echocardiography and no clinical signs and symptoms of heart failure). * alcohol or drug abuse, * malignancy (unless healed or remission \> 5 years) * pregnancy * know allergy to contrast medium * participation in another study within the last month
metabolites of tear fluid

Conditions: Healthy Subjects

Summary: the pilot trial evaluates the use of modified schirmer strips and is designed to evaluate inter-individual range of metabolites in tear film.

the variability of tear film metabolites should be investigated in a sample of ophthalmologists in preparation for a pilot study in patients eye diseases. the easy accessibility of the tear fluid and the lack of invasiveness of the study make it promising and sensible to determine the concentration of various tear film metabolites. because attention has so far focused primarily on the quantitative and qualitative analysis of tear film proteins, many metabolites have so far only been shown to be contained in tears. however, before the suitability of the measured values as a predictive parameter of the ocular surface for pathologies can be examined and assessed, it is necessary to determine the scattering variables in a sample of healthy volunteers. thus, reference areas are to be defined for later investigations in order to enable reliable case number planning thereafter. repeated determinations at different times and on different days make it possible in particular to detect a time-dependent relationship in view of the dynamic variability of the tear film. the functional significance of certain metabolites can not yet be assessed in the establishment phase. however, the data may provide important information for the interpretation of a later, planned feasibility study with diseased patients or the influence of applied eye drops.

Eligibility criteria:
inclusion criteria: * healthy subjects at age \> 18 years exclusion criteria: * in the case of subjects with a mental disability or legal guardianship, due to possible conflicts for the caregivers, a data evaluation and recording should in principle be dispensed with. * subjects who have had any eye drops within the last 4 weeks, e.g. lubricants were used * subjects undergoing clinical examination for symptoms of wetting disorder or morphological changes related to eye disease

Keywords: tear, metabolite